Matrix metalloproteinases in pneumonia

Clinica Chimica Acta

Volumn 433, Issue , 2014, Pages 272-277

  Chiang, Ting Yen ^a   Tsao, Shih Ming ^a,b   Yeh, Chao Bin ^a,b   Yang, Shun Fa ^a,b  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Matrix metalloproteinase; Pneumonia

Indexed keywords

GELATINASE A; GELATINASE B; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 28; NEUTROPHIL COLLAGENASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; STROMELYSIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

COMMUNITY ACQUIRED PNEUMONIA; DISEASE CLASSIFICATION; DISEASE MARKER; DISEASE SEVERITY; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME RELEASE; EXTRACELLULAR MATRIX; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PATHOGENESIS; PNEUMONIA; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; REVIEW; STRUCTURE ACTIVITY RELATION; VENTILATOR ASSOCIATED PNEUMONIA; ENZYMOLOGY; INFLAMMATION; METABOLISM; PATHOLOGY;

HUMANS; INFLAMMATION; MATRIX METALLOPROTEINASES; PNEUMONIA;

EID: 84899002650     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.03.031     Document Type: Review

References (77)

1. WHO The top 10 causes of death 2013.
2. Metlay J.P., Fine M.J. Testing strategies in the initial management of patients with community-acquired pneumonia. Ann Intern Med 2003, 138:109-118.
3. Baron E.J., Miller J.M., Weinstein M.P., Richter S.S., Gilligan P.H., Thomson R.B., et al. A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2013 recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM)(a). Clin Infect Dis 2013, 57:e22-e121.
4. Cheng C.W., Chien M.H., Su S.C., Yang S.F. New markers in pneumonia. Clin Chim Acta 2013, 419:19-25.
5. Harrison's™ Principles of internal medicine eighteenth edition 2011, A.S.F. Longo, L. Dan, L. Kasper Dennis, L. Hauser Stephen, J.L. Jameson, J. Loscalzo (Eds.).
6. Anand N., Kollef M.H. The alphabet soup of pneumonia: CAP, HAP, HCAP, NHAP, and VAP. Semin Respir Crit Care Med 2009, 30:3-9.
7. America.ATSIDSo Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416.
8. WHO Pneumonia 2013.
9. Jereb M., Kotar T. Usefulness of procalcitonin to differentiate typical from atypical community-acquired pneumonia. Wien Klin Wochenschr 2006, 118:170-174.
10. Parks W.C., Wilson C.L., Lopez-Boado Y.S. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004, 4:617-629.
11. Nagase H., Woessner J.F. Matrix metalloproteinases. J Biol Chem 1999, 274:21491-21494.
12. Pardo A., Selman M. Matrix metalloproteases in aberrant fibrotic tissue remodeling. Proc Am Thorac Soc 2006, 3:383-388.
13. Sternlicht M.D., Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001, 17:463-516.
14. Van Wart H.E., Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci U S A 1990, 87:5578-5582.
15. Bode W., Gomis-Ruth F.X., Stockler W. Astacins, serralysins, snake venom and matrix metalloproteinases exhibit identical zinc-binding environments (HEXXHXXGXXH and Met-turn) and topologies and should be grouped into a common family, the 'metzincins'. FEBS Lett 1993, 331:134-140.
16. Khokha R., Murthy A., Weiss A. Metalloproteinases and their natural inhibitors in inflammation and immunity. Nat Rev Immunol 2013, 13:649-665.
17. Bode W. A helping hand for collagenases: the haemopexin-like domain. Structure 1995, 3:527-530.
18. Allan J.A., Docherty A.J., Barker P.J., Huskisson N.S., Reynolds J.J., Murphy G. Binding of gelatinases A and B to type-I collagen and other matrix components. Biochem J 1995, 309(Pt 1):299-306.
19. Gururajan R., Grenet J., Lahti J.M., Kidd V.J. Isolation and characterization of two novel metalloproteinase genes linked to the Cdc2L locus on human chromosome 1p36.3. Genomics 1998, 52:101-106.
20. Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003, 92:827-839.
21. Kheradmand F., Werner E., Tremble P., Symons M., Werb Z. Role of Rac1 and oxygen radicals in collagenase-1 expression induced by cell shape change. Science 1998, 280:898-902.
22. Brenneisen P., Wenk J., Klotz L.O., Wlaschek M., Briviba K., Krieg T., et al. Central role of ferrous/ferric iron in the ultraviolet B irradiation-mediated signaling pathway leading to increased interstitial collagenase (matrix-degrading metalloprotease (MMP)-1) and stromelysin-1 (MMP-3) mRNA levels in cultured human dermal fibroblasts. J Biol Chem 1998, 273:5279-5287.
23. Reunanen N., Foschi M., Han J., Kahari V.M. Activation of extracellular signal-regulated kinase 1/2 inhibits type I collagen expression by human skin fibroblasts. J Biol Chem 2000, 275:34634-34639.
24. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem 1997, 378:151-160.
25. Gill S., Wight T.N., Frevert C.W. Proteoglycans: key regulators of pulmonary inflammation and the innate immune response to lung infection. Anat Rec (Hoboken) 2010, 293:968-981.
26. Bals R., Hiemstra P.S. Innate immunity in the lung: how epithelial cells fight against respiratory pathogens. Eur Respir J 2004, 23:327-333.
27. Boucher R.C. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J 2004, 23:146-158.
28. Kassim S.Y., Gharib S.A., Mecham B.H., Birkland T.P., Parks W.C., McGuire J.K. Individual matrix metalloproteinases control distinct transcriptional responses in airway epithelial cells infected with Pseudomonas aeruginosa. Infect Immun 2007, 75:5640-5650.
29. Lopez-Boado Y.S., Wilson C.L., Parks W.C. Regulation of matrilysin expression in airway epithelial cells by Pseudomonas aeruginosa flagellin. J Biol Chem 2001, 276:41417-41423.
30. Manicone A.M., Birkland T.P., Lin M., Betsuyaku T., van Rooijen N., Lohi J., et al. Epilysin (MMP-28) restrains early macrophage recruitment in Pseudomonas aeruginosa pneumonia. J Immunol 2009, 182:3866-3876.
31. Li Q., Park P.W., Wilson C.L., Parks W.C. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 2002, 111:635-646.
32. Lopez-Boado Y.S., Wilson C.L., Hooper L.V., Gordon J.I., Hultgren S.J., Parks W.C. Bacterial exposure induces and activates matrilysin in mucosal epithelial cells. J Cell Biol 2000, 148:1305-1315.
33. McGuire J.K., Li Q., Parks W.C. Matrilysin (matrix metalloproteinase-7) mediates E-cadherin ectodomain shedding in injured lung epithelium. Am J Pathol 2003, 162:1831-1843.
34. Dunsmore S.E., Saarialho-Kere U.K., Roby J.D., Wilson C.L., Matrisian L.M., Welgus H.G., et al. Matrilysin expression and function in airway epithelium. J Clin Invest 1998, 102:1321-1331.
35. Wilson C.L., Ouellette A.J., Satchell D.P., Ayabe T., Lopez-Boado Y.S., Stratman J.L., et al. Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. Science 1999, 286:113-117.
36. Grassme H., Kirschnek S., Riethmueller J., Riehle A., von Kurthy G., Lang F., et al. CD95/CD95 ligand interactions on epithelial cells in host defense to Pseudomonas aeruginosa. Science 2000, 290:527-530.
37. Powell W.C., Fingleton B., Wilson C.L., Boothby M., Matrisian L.M. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr Biol 1999, 9:1441-1447.
38. Nakamura M., Miyamoto S., Maeda H., Ishii G., Hasebe T., Chiba T., et al. Matrix metalloproteinase-7 degrades all insulin-like growth factor binding proteins and facilitates insulin-like growth factor bioavailability. Biochem Biophys Res Commun 2005, 333:1011-1016.
39. Selman M., Pardo A. Idiopathic pulmonary fibrosis: an epithelial/fibroblastic cross-talk disorder. Respir Res 2002, 3:3.
40. Wilson C.L., Heppner K.J., Labosky P.A., Hogan B.L., Matrisian L.M. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci U S A 1997, 94:1402-1407.
41. Zuo F., Kaminski N., Eugui E., Allard J., Yakhini Z., Ben-Dor A., et al. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci U S A 2002, 99:6292-6297.
42. + effectors in promoting tubular injury following allogeneic renal transplantation. J Immunol 2005, 175:2868-2879.
43. Kilshaw P.J., Murant S.J. Expression and regulation of beta 7(beta p) integrins on mouse lymphocytes: relevance to the mucosal immune system. Eur J Immunol 1991, 21:2591-2597.
44. Schaaf B., Liebau C., Kurowski V., Droemann D., Dalhoff K. Hospital acquired pneumonia with high-risk bacteria is associated with increased pulmonary matrix metalloproteinase activity. BMC Pulm Med 2008, 8:12.
45. Brown G.M., Brown D.M., Donaldson K., Drost E., MacNee W. Neutrophil sequestration in rat lungs. Thorax 1995, 50:661-667.
46. Delclaux C., Delacourt C., D'Ortho M.P., Boyer V., Lafuma C., Harf A. Role of gelatinase B and elastase in human polymorphonuclear neutrophil migration across basement membrane. Am J Respir Cell Mol Biol 1996, 14:288-295.
47. Borregaard N., Cowland J.B. Granules of the human neutrophilic polymorphonuclear leukocyte. Blood 1997, 89:3503-3521.
48. Rosendahl A., Bergmann S., Hammerschmidt S., Goldmann O., Medina E. Lung dendritic cells facilitate extrapulmonary bacterial dissemination during pneumococcal pneumonia. Front Cell Infect Microbiol 2013, 3:21.
49. Opdenakker G., Van den Steen P.E., Dubois B., Nelissen I., Van Coillie E., Masure S., et al. Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol 2001, 69:851-859.
50. Price B., Dennison C., Tschesche H., Elliott E. Neutrophil tissue inhibitor of matrix metalloproteinases-1 occurs in novel vesicles that do not fuse with the phagosome. J Biol Chem 2000, 275:28308-28315.
51. Hartog C.M., Wermelt J.A., Sommerfeld C.O., Eichler W., Dalhoff K., Braun J. Pulmonary matrix metalloproteinase excess in hospital-acquired pneumonia. Am J Respir Crit Care Med 2003, 167:593-598.
52. Oggioni M.R., Memmi G., Maggi T., Chiavolini D., Iannelli F., Pozzi G. Pneumococcal zinc metalloproteinase ZmpC cleaves human matrix metalloproteinase 9 and is a virulence factor in experimental pneumonia. Mol Microbiol 2003, 49:795-805.
53. Yamashiro S., Kamohara H., Wang J.M., Yang D., Gong W.H., Yoshimura T. Phenotypic and functional change of cytokine-activated neutrophils: inflammatory neutrophils are heterogeneous and enhance adaptive immune responses. J Leukoc Biol 2001, 69:698-704.
54. Taggart C.C., Greene C.M., Carroll T.P., O'Neill S.J., McElvaney N.G. Elastolytic proteases: inflammation resolution and dysregulation in chronic infective lung disease. Am J Respir Crit Care Med 2005, 171:1070-1076.
55. Chang S.H., Dong C. IL-17F: regulation, signaling and function in inflammation. Cytokine 2009, 46:7-11.
56. Kumagai K., Ohno I., Okada S., Ohkawara Y., Suzuki K., Shinya T., et al. Inhibition of matrix metalloproteinases prevents allergen-induced airway inflammation in a murine model of asthma. J Immunol 1999, 162:4212-4219.
57. Hong J.S., Greenlee K.J., Pitchumani R., Lee S.H., Song L.Z., Shan M., et al. Dual protective mechanisms of matrix metalloproteinases 2 and 9 in immune defense against Streptococcus pneumoniae. J Immunol 2011, 186:6427-6436.
58. Shapiro S.D. Elastolytic metalloproteinases produced by human mononuclear phagocytes. Potential roles in destructive lung disease. Am J Respir Crit Care Med 1994, 150:S160-S164.
59. Torii K., Iida K., Miyazaki Y., Saga S., Kondoh Y., Taniguchi H., et al. Higher concentrations of matrix metalloproteinases in bronchoalveolar lavage fluid of patients with adult respiratory distress syndrome. Am J Respir Crit Care Med 1997, 155:43-46.
60. Lindberg R.L., Sorsa T., Tervahartiala T., Hoffmann F., Mellanen L., Kappos L., et al. Gelatinase B [matrix metalloproteinase (MMP)-9] and collagenases (MMP-8/-13) are upregulated in cerebrospinal fluid during aseptic and bacterial meningitis in children. Neuropathol Appl Neurobiol 2006, 32:304-317.
61. El-Solh A.A., Amsterdam D., Alhajhusain A., Akinnusi M.E., Saliba R.G., Lynch S.V., et al. Matrix metalloproteases in bronchoalveolar lavage fluid of patients with type III Pseudomonas aeruginosa pneumonia. J Infect 2009, 59:49-55.
62. Guideline for prevention of nosocomial pneumonia. Centers for disease control and prevention. Respir Care 1994, 39:1191-1236.
63. Lynch J.P. Hospital-acquired pneumonia: risk factors, microbiology, and treatment. Chest 2001, 119:373S-384S.
64. Zheng L., Lam W.K., Tipoe G.L., Shum I.H., Yan C., Leung R., et al. Overexpression of matrix metalloproteinase-8 and -9 in bronchiectatic airways in vivo. Eur Respir J 2002, 20:170-176.
65. Sagel S.D., Kapsner R.K., Osberg I. Induced sputum matrix metalloproteinase-9 correlates with lung function and airway inflammation in children with cystic fibrosis. Pediatr Pulmonol 2005, 39:224-232.
66. Chastre J., Fagon J.Y. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002, 165:867-903.
67. Conway Morris A., Kefala K., Wilkinson T.S., Dhaliwal K., Farrell L., Walsh T., et al. C5a mediates peripheral blood neutrophil dysfunction in critically ill patients. Am J Respir Crit Care Med 2009, 180:19-28.
68. Wilkinson T.S., Morris A.C., Kefala K., O'Kane C.M., Moore N.R., Booth N.A., et al. Ventilator-associated pneumonia is characterized by excessive release of neutrophil proteases in the lung. Chest 2012, 142:1425-1432.
69. Yang S.F., Chu S.C., Chiang I.C., Kuo W.F., Chiou H.L., Chou F.P., et al. Excessive matrix metalloproteinase-9 in the plasma of community-acquired pneumonia. Clin Chim Acta 2005, 352:209-215.
70. Chiang T.Y., Shyu L.Y., Tsao T.C., Chien M.H., Tsao S.M., Lee Y.T., et al. Elevated plasma matrix metalloproteinase-9 protein and its gene polymorphism in patients with community-acquired pneumonia. Clin Chem Lab Med 2012, 50:449-454.
71. Baker A.H., Edwards D.R., Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002, 115:3719-3727.
72. Chiang T.Y., Yu Y.L., Lin C.W., Tsao S.M., Yang S.F., Yeh C.B. The circulating level of MMP-9 and its ratio to TIMP-1 as a predictor of severity in patients with community-acquired pneumonia. Clin Chim Acta 2013, 424:261-266.
73. Cowland J.B., Borregaard N. Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics 1997, 45:17-23.
74. Yan L., Borregaard N., Kjeldsen L., Moses M.A. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 2001, 276:37258-37265.
75. Yeh Y.H., Chang J.L., Hsiao P.C., Tsao S.M., Lin C.H., Kao S.J., et al. Circulating level of lipocalin 2 as a predictor of severity in patients with community-acquired pneumonia. J Clin Lab Anal 2013, 27:253-260.
76. Waites K.B., Talkington D.F. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 2004, 17:697-728.
77. Puljiz I., Markotic A., Cvetko Krajinovic L., Guzvinec M., Polasek O., Kuzman I. Mycoplasma pneumoniae in adult community-acquired pneumonia increases matrix metalloproteinase-9 serum level and induces its gene expression in peripheral blood mononuclear cells. Med Sci Monit 2012, 18:CR500-CR505.